Y-mAbs Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
YMAB Nasdaq 2836 www.ymabs.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Y-mAbs Therapeutics, Inc.

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate - Jun 11th, 2025 7:22 am
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline - May 28th, 2025 4:35 am
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025 - May 26th, 2025 8:57 pm
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - May 26th, 2025 8:00 am
Y-mAbs Therapeutics First Quarter 2025 Earnings: Beats Expectations - May 15th, 2025 5:14 am
Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension - May 14th, 2025 7:18 am
Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges - May 14th, 2025 1:05 am
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates - May 13th, 2025 5:45 am
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025 - May 13th, 2025 5:05 am
Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments - May 13th, 2025 4:35 am
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®) - May 7th, 2025 5:05 am
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025 - May 6th, 2025 5:05 am
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline - Apr 30th, 2025 8:01 am
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline - Apr 29th, 2025 8:01 am
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting - Apr 27th, 2025 1:00 pm
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures - Apr 27th, 2025 8:45 am
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma - Apr 25th, 2025 5:35 am
Bearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimates - Mar 9th, 2025 8:11 am
Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Call Highlights: Strategic Realignment and ... - Mar 5th, 2025 12:04 am
Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 79% loss from investing in the stock five years ago - Mar 4th, 2025 7:38 am